GSK to fill up to 60 million Novavax vaccine doses for Britain
Reuters
Published Mar 29, 2021 19:18
By Ludwig Burger
FRANKFURT (Reuters) - GlaxoSmithKline has agreed in principle to handle the final part of the manufacturing process for up to 60 million doses of Novavax's COVID-19 vaccine for use in Britain, widening the company's role in the fight against the pandemic.
GSK said in a statement on Monday it would step in from May for the final production steps and bottling into vials known as "fill and finish" at its Barnard Castle facility in the northeast of England, without compromising supply of other vital medicines and vaccines.
A detailed agreement with the U.S. biotech firm Novavax and the UK government's vaccines taskforce has yet to be signed, it added.
Britain struck a deal to buy 60 million doses of Novavax’s vaccine candidate in August.
Novavax will manufacture some of the vaccine using Fujifilm Diosynth Biotechnologies facilities in Stockton-on-Tees, northern England.
Speaking at a news conference on Monday, Britain's Prime Minister Boris Johnson said production there had started, in anticipation of the vaccine's approval by the Medicines and Healthcare products Regulatory Agency (MHRA).
He said the effort would provide 50 million to 60 million doses made in the UK.
Talks between Novavax and the European Union over supply of as much as 200 million doses have dragged on, with the U.S. biotech firm citing pandemic-related raw materials shortages.
GSK and partner Sanofi (PA:SASY) suffered a development setback in December, delaying their jointly developed vaccine. But the British group has since agreed to collaborate on production and vaccine development with Germany's CureVac.
Novavax Inc's COVID-19 vaccine was shown this month to be 96% effective in preventing cases caused by the original version of the coronavirus in a trial in Britain.The vaccine was also found at the time to be 86% effective in protecting against the more contagious B117 variant.
(Additional Reporting by Alistair Smout in London; Editing by Gareth Jones and Cynthia Osterman)
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.